NEUP
Neuphoria Therapeutics Inc.Healthcare·Medical - Pharmaceuticals
$5.31
$29M market cap
Revenue
$-15.7M
Free Cash Flow
$59.5M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
0.5x
EV/FCF
0.2x
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
2-Year Price History
$5.48-35.7%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q3 | 0.0 | -1.0 | -1.2 | -0.5 | -3.9 | -3.9 | -0.0 | 19.4 | 0.0 | 5.4 | -27.2% | -- | -- |
| Act | 2026-Q2 | 0.0 | -2.2 | -4.1 | 1.9 | -6.4 | -6.4 | -0.0 | 22.2 | 0.1 | 4.5 | -93.4% | -- | -- |
| Act | 2026-Q1 | 0.0 | -5.5 | -5.7 | -9.9 | -3.8 | -3.8 | -0.0 | 13.7 | 0.1 | 2.3 | <-999% | -- | -- |
| Act | 2025-Q4 | -15.7 | -846.8 | -1,134 | -378.2 | 73.6 | 73.6 | -0.0 | 21.6 | 0.2 | 1.6 | <-999% | -- | -- |
Historical Valuation
Multiples vs the company's own history — cheap or rich relative to itself? Historical fiscal years, then TTM, then forward projections (E). Forward rows hold today's price against projected earnings, so the multiple compresses if the company grows into it.
| Year | Price | Rev Gr | EBITDA % | EBITDA | EV/EBITDA | EV/FCF | P/E | P/S |
|---|---|---|---|---|---|---|---|---|
| TTM | 5.31 | 0.0% | 5461.9% | -855 | 0.0× | 0.0× | 0.0× | 0.0× |
EBITDA in reporting-currency $M. Historical multiples use year-end market cap (split-adjusted price history); TTM & forward years use today's.
Valuation & Metrics
Market Stats
Price$5.31
Market Cap$29M
Enterprise Value$9M
P/S Ratio0.0x
P/FCF0.5x
EV/FCF0.2x
FCF Margin (TTM)0.0%
FCF Yield207.2%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$-15.7M
Net Income$-386.7M
Free Cash Flow$59.5M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-12452.4%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares0.1M
Days to Cover1.5
Change (vs Prior)+97.4%
Need at least 2 settlement dates for chart
Employees
Headcount8
Revenue / Employee$-1,957,839
Gross Profit / Employee$-1,937,212
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
22.9%(+19.5% YoY)
15 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
2.7%(+2.7% YoY)
3 filers
Vanguard, iShares, SPDR
Market makers
0.2%(+0.2% YoY)
1 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | $3.6M | $3.86 | +$0 | +$3.4M | +3.0% | $633M |
| AdvisorShares Investments LLC | $632K | $4.69 | +$86K | +$349K | -7.6% | $549M |
| Shay Capital LLC | $615K | $3.88 | −$73K | +$615K | +0.3% | $704M |
| BALYASNY ASSET MANAGEMENT LLC | $579K | $4.07 | +$579K | +$579K | -0.4% | $48.01B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $401K | $4.07 | +$401K | +$401K | — | $4.04T |
| Squadron Capital Management LLC | $312K | $4.07 | +$312K | +$312K | +17.8% | $250M |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $212K | $5.98 | +$141K | +$212K | +2.3% | $1.61T |
| Ikarian Capital, LLC | $193K | $3.88 | +$0 | +$193K | -8.8% | $698M |
| VANGUARD FIDUCIARY TRUST COPassive | $137K | $4.07 | +$137K | +$137K | — | $395.83B |
| ADAR1 Capital Management, LLC | $122K | $3.88 | +$0 | +$122K | +8.3% | $1.64B |
| FNY Investment Advisers, LLC | $107K | $3.88 | +$0 | +$107K | -0.7% | $225M |
| CITADEL ADVISORS LLC | $79K | $6.36 | +$19K | +$79K | -0.4% | $138.22B |
| BOOTHBAY FUND MANAGEMENT, LLC | $57K | $3.88 | +$0 | +$57K | -0.4% | $4.25B |
| Virtu Financial LLCMM | $49K | $4.07 | +$49K | +$49K | -2.0% | $2.41B |
| COMMONWEALTH EQUITY SERVICES, LLC | $46K | $3.88 | +$0 | +$46K | -0.3% | $71.14B |
| Merck & Co., Inc. | $41K | $3.43 | +$0 | +$0 | +1.4% | $349M |
| UBS Group AG | $9K | $3.55 | +$3K | +$9K | -0.3% | $562.11B |
| RHUMBLINE ADVISERS | $0 | $3.49 | +$0 | −$0 | +0.4% | $116.90B |
| MORGAN STANLEY | $0 | $3.83 | +$0 | +$0 | -0.3% | $1.65T |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
+1.67%
avg per quarter
Holders (ex-self)
+1.67%
excl. this stock
Buyers (this Q)
+4.23%
10 buyers · $0.00B in
Sellers (this Q)
+0.26%
1 sellers · $0.00B out
alpha coverage: 92% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+34.7%
how holders react when this stock falls
On quiet Qs
+0.9%
−10% to +10% baseline
On rallies (+10%+)
-3.6%
how they react when this stock rises
Holders' portfolio flow this Q
+8.3%
inflows — adds are organic
Sellers' portfolio flow this Q
+13.9%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-2.2%
Holder mid (any stock)
-7.0%
Holder rally (any stock)
-0.6%
Biggest decreases this quarter
New buyers this quarter
Top-5 holders · 80.9%
Lynx1 Capital Management LP--
AdvisorShares Investments LLC--
Shay Capital LLC--
BALYASNY ASSET MANAGEMENT LLC--
VANGUARD CAPITAL MANAGEMENT LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
Lynx1 Capital Management LP875KAdvisorShares Investments LLC155KShay Capital LLC151KBALYASNY ASSET MANAGEMENT LLC142KProsperity Wealth Management, Inc.—Squadron Capital Management LLC77KDIADEMA PARTNERS LP—MILLENNIUM MANAGEMENT LLC—Ikarian Capital, LLC47KADAR1 Capital Management, LLC30K
Analyst Coverage
Analyst Coverage
Price Targets
Last Year (1 analysts)$7.003180.0%
Current Price$5.31
Analyst Ratings
1
1
Buy: 1Hold: 1Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$3.28M
1 txn · 1 insider · 639,110 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2025-10-21 | BUY | Lynx1 Capital Management LP | 10 percent owner | 639,110 | $5.14 | $3.28M | $4.50M |
Order Flow (FINRA, ~3w lag)
31.8%retail-7.4pp
8.6%dark-1.0pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Neuphoria Therapeutics: A Ghost in the Nasdaq Shell Powered by Accounting Magic
Overall Risk
9/10
Fraud
4/10
Dilution
10/10
Insolvency
7/10
Earnings Overstated
9/10
Hidden Liabilities
5/10
Legal
4/10
Audit Warnings
8/10
Hidden Upside
2/10
Contextually Acceptable
2/10